|
Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.〔(【引用サイトリンク】publisher=American Medical Association )〕 Tralokinumab was discovered by Cambridge Antibody Technology scientists, using Ribosome Display, as CAT-354 and taken through pre-clinical development. As of April 2012 it is being developed by MedImmune, a member of the AstraZeneca group, where it is currently in Ph3 testing for asthma and Ph2 testing for atopic dermatitis.〔(【引用サイトリンク】url=http://www.medimmune.com/research/pipeline )〕〔(【引用サイトリンク】url=http://www.clinicaltrials.gov/ct2/results?term=CAT-354 )〕 This makes it one of the few fully internally discovered and developed drug candidates in AstraZeneca's late stage development pipeline. == Discovery and Development == Tralokinumab was discovered by Cambridge Antibody Technology scientists using protein optimization based on Ribosome Display. In March 2008, MedImmune LLC initiated a study to assess bioavailability and pharmacokinetics of CAT-354. On 21 July 2011, MedImmune LLC initiated a Ph2b, randomized, double-blind Study to evaluate the efficacy of tralokinumab in adults with asthma. On 29 November 2011, AstraZeneca and MedImmune Ltd announced their intention to start a Ph2 trial to evaluate the efficacy and safety of tralokinumab in patients with active, moderate-to-severe ulcerative colitis. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Tralokinumab」の詳細全文を読む スポンサード リンク
|